Table.
Clinical details of patients and catecholamine concentrations
| Case No | Age (years) | Sex | Body mass index (kg/m2) | Clozapine dose (mg/day) and duration of treatment* | Other drugs | Heart rate (beats/min) | Blood pressure (mm Hg) | 24 hour urinary catecholamine concentration (μmol) (reference range) |
|---|---|---|---|---|---|---|---|---|
| 1 | 27 | Male | 31 | 400 for 2 months | Fluoxetine 20 mg daily | 110 | 170/120 | Noradrenaline 1.68 (<0.59), vanillylmandelic acid 54 (<35) |
| 2 | 28 | Female | 38 | 700 for 12 months | Bendrofluazide 2.5 mg daily | 104 | 143/112† | Noradrenaline 1.02 (0.08-0.45) |
| 3 | 38 | Male | 40 | 900 for 18 months | Sulpiride 600 mg, venlafaxine 150 mg, and metformin 500 mg twice daily | 130 | 156/100 | Noradrenaline 0.53 (0.07-0.48), normetadrenaline 4.3 (0-3.00) |
| 4 | 22 | Male | 30 | 600 for 3 months | Sulpiride 200 mg daily and paroxetine 50 mg daily | NA | 180/120 | Noradrenaline 0.90 (0.07-0.48), normetadrenaline 4.6 (0-3.00) |
NA=not available. *Before measurement of 24 hour urinary catecholamine concentration.
†
Average during ambulatory monitoring.